CDK4/6 inhibition: What’s happening beyond CDK4/6 inhibition may also matter
-
-
REFERENCES
[1] Sherr, C.J., Beach, D., and Shapiro, G.I. (2016). Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov. 6: 353−367. DOI: 10.1158/2159-8290.CD-15-0894. [2] Goel, S., DeCristo, M.J., Watt, A.C., et al. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature 548: 471−475. DOI: 10.1038/nature23465. [3] Scirocchi, F., Scagnoli, S., Botticelli, A., et al. (2022). Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response. EBioMedicine 79: 104010. DOI: 10.1016/j.ebiom.2022.104010. [4] Zhang, J., Bu, X., Wang, H., et al. (2018). Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553: 91−95. DOI: 10.1038/nature25015. -
ABOUT THIS ARTICLE
Cite this article:
Fan Y. and Xu B. (2023). CDK4/6 inhibition: What’s happening beyond CDK4/6 inhibition may also matter. The Innovation Medicine 1(2), 100016. https://doi.org/10.59717/j.xinn-med.2023.100016
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Fan Y. and Xu B. (2023). CDK4/6 inhibition: What’s happening beyond CDK4/6 inhibition may also matter. The Innovation Medicine 1(2), 100016. https://doi.org/10.59717/j.xinn-med.2023.100016
Format
Content
DownLoad:
-
Figure 1.
The potential impact of CDK4/6 inhibitors on the immune system
